What biomarker tests are recommended for Breast Cancer

Biomarker Testing for Breast Cancer

Biomarker testing is a crucial part of breast cancer care. These tests examine your tumor tissue (or sometimes blood) to identify specific characteristics that guide treatment decisions. Let me walk you through what's typically recommended.

Core Biomarker Tests (Standard for All Breast Cancers)

According to NCCN Guidelines for Patients: Invasive Breast Cancer, every breast cancer diagnosis should include testing for:

Hormone Receptors

• Estrogen Receptor (ER): Tests whether cancer cells have receptors that respond to estrogen. ER-positive (ER+) cancers grow when exposed to estrogen and typically respond well to hormone-blocking therapies.
• Progesterone Receptor (PR): Similar to ER, this checks if cancer cells respond to progesterone. PR expression often suggests the tumor is estrogen-dependent.

What this means: If your cancer is hormone receptor-positive (HR+), your doctor can use endocrine therapy (hormone treatments) to block these signals and slow cancer growth.

HER2 Status

• HER2 (Human Epidermal Growth Factor Receptor 2): This protein drives cell growth. HER2-positive cancers can be targeted with specific drugs like trastuzumab (Herceptin) or other HER2-directed therapies.

What this means: HER2 status determines whether you're eligible for targeted therapies that specifically attack this protein.

---

Additional Biomarker Tests (Recommended Based on Your Situation)

The NCCN Guidelines note that additional biomarker testing is "more commonly done in metastatic breast cancer" (cancer that has spread), but may be recommended for your individual case. These include:

Tumor Mutation Testing

Your tumor sample may be tested for specific DNA mutations using methods like:

• Next-generation sequencing (NGS)
• FISH, ISH, or PCR testing

Mutations that can be targeted with therapy include:

• PIK3CA: Can be treated with specific targeted drugs
• ESR1: Tested in hormone receptor-positive tumors
• NTRK gene fusions: Rare, but can be treated with larotrectinib (Vitrakvi) or entrectinib (Rozlytrek)
• RET gene fusions: Can be treated with selpercatinib (Retevmo) in HR+/HER2- cancers

Tumor Markers (Blood Tests)

Your blood may be tested for proteins called tumor markers:

• CEA (carcinoembryonic antigen)
• CA 15-3
• CA 27.29

Important note: According to NCCN Guidelines, "not everyone has elevated levels of these markers and tumor markers alone are not a reliable method of detecting breast cancer." They're used to monitor treatment response, not for diagnosis.

Liquid Biopsy (Blood-Based Testing)

Some labs can detect circulating tumor DNA (ctDNA) in your blood. This is useful when:

• Your tumor sample has been used up by other testing
• You need ongoing monitoring of disease progression

---

How These Tests Guide Treatment

NCCN Guidelines emphasize that "your treatment team will recommend the best types of biomarker testing that are important for you." Here's the clinical reasoning:

• ER+/HER2- cancers → Typically treated with hormone therapy, sometimes with CDK4/6 inhibitors
• HER2+ cancers → Treated with HER2-targeted therapies (antibodies or kinase inhibitors)
• Triple-negative cancers (ER-, PR-, HER2-) → Often treated with chemotherapy and/or immunotherapy
• Specific mutations → May open doors to targeted drugs or clinical trials

---

Questions to Ask Your Healthcare Team

Since biomarker testing is personalized to your situation, here are important questions:

1. Which biomarker tests have been done on my tumor, and what were the results?
2. Are there additional biomarker tests you recommend for my specific type of breast cancer?
3. How do my biomarker results affect my treatment options?
4. If I have a mutation like PIK3CA or NTRK, are there targeted therapies available for me?
5. Will you retest my tumor if my cancer progresses, since biomarkers can change?

---

Key Takeaway

Biomarker testing transforms breast cancer from a one-size-fits-all diagnosis into a personalized roadmap for treatment. The core tests (ER, PR, HER2) are standard, while additional testing depends on your cancer type, stage, and individual factors. Your oncologist will determine which tests are most valuable for YOUR specific case.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.